Edison signs multi-billion dollar deal with DSP
This article was originally published in Scrip
Edison Pharmaceuticals has signed a multi-billion dollar deal with Japanese pharma giant Dainippon Sumitomo Pharma (DSP) for the development of the former company's drugs targeting cellular energy metabolism. However, the deal includes only $10m in upfront payments, plus R&D funding of $40m.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.